The pharmaceutical giant thus intends to “double the production capacity of monoclonal antibodies” at its Vitry-sur-Seine site.
:quality(50)/2023/07/06/64a68815cd1a7_placeholder-36b69ec8.png)
Published
Update
Reading time: 1 min
:quality(50)/2024/05/13/000-32hp86c-6641b8a3aa47a133326334.jpg)
The French pharmaceutical group Sanofi has announced an investment of more than a billion euros in the production of medicines in France, with the construction of a new factory on its site in Vitry-sur-Seine (Val-de-Marne) . This new establishment “will double the production capacity of monoclonal antibodies on the site”specifies the group in a press release published Monday May 13.
The Minister Delegate in charge of Health, Frédéric Valletoux, “welcomes this announcement as well as the investments revealed by Pfizer and AstraZeneca”, in a reaction sent to AFP. The American Pfizer and the British AstraZeneca announced on Sunday that they were committing to investing several hundred million additional euros in health in France.
The group specifies that “several biomedicines in development among Sanofi’s 12 potential blockbusters currently in clinical study could thus be produced in Vitry”a site that has switched over the last decade from chemical medications to biological treatments.
